PDE4B is one of the genes that are highly expressed in refractory DLBCL patients, and one of the main downstream targets of roflumilast is Mcl-1, indicating that this agent may be useful in overcoming chemoresistance by repressing Mcl-1 levels. The gene discussed is MCL1; the disease is diffuse large B-cell lymphoma.